Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
A single-cell analysis solution that revolutionizes efficiency in drug discovery research by automating the collection of specific cells and intracellular components
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
Preclinical data demonstrate sotrovimab, authorised in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron
She replaces Victoria Tabiner, who is stepping down after 10 years at Sygnature
According to a survey conducted by FOGSI last year, 92% of the doctors opined that anaemia due to iron deficiency can be eradicated in five years
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent
The Omicron variant, which was designated a variant of concern by the World Health Organization (WHO), has more than 30 mutations in the spike protein alone
It’s a two-dose vaccine administered 28 days apart
Subscribe To Our Newsletter & Stay Updated
